Status:

UNKNOWN

Soft Tissue Tenderness and Fibromyalgia Among Schizophrenia Patients.

Lead Sponsor:

HaEmek Medical Center, Israel

Conditions:

Fibromyalgia

Schizophrenia

Eligibility:

All Genders

18+ years

Brief Summary

Numerous studies reported on comorbidity of fibromyalgia and psychiatric disorders. Approximately 30% of patients with fibromyalgia have major depression at the time of diagnosis; the lifetime prevale...

Eligibility Criteria

Inclusion

  • Women above 18 years of age.
  • Patients must meet DSM-5 criteria for a diagnosis of schizophrenia.
  • A stabled mental state.
  • If hospitalized, patients are scheduled for discharge on the basis of clinical assessment of psychiatric symptoms.

Exclusion

  • Mental co-morbidity.
  • Diagnosis of myofascial pain syndrome or chronic fatigue syndrome.
  • Alcohol or drug use.
  • Usage of any pain reliever medications during the week before recruitment.

Key Trial Info

Start Date :

June 10 2021

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

September 10 2024

Estimated Enrollment :

286 Patients enrolled

Trial Details

Trial ID

NCT05328518

Start Date

June 10 2021

End Date

September 10 2024

Last Update

April 14 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Haemek medical center

Afula, Israel, 1910500

Soft Tissue Tenderness and Fibromyalgia Among Schizophrenia Patients. | DecenTrialz